Zepbound and the company's diabetes drug Mounjaro now make up over half of U.S. GLP-1 prescriptions, outpacing the combined 46% share of Novo ... offices near the West Village?," ...

Zepbound and the company's diabetes drug Mounjaro now make up over half of U.S. GLP-1 prescriptions, outpacing the combined 46% share of Novo ... offices near the West Village?," ...

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

Despite being the first to market in the latest generation of GLP-1 drugs, notably with its well-known diabetes drug Ozempic and weight-loss drug Wegovy, Novo Nordisk has recently faced several ...

who has led Novo Nordisk for eight years. The move reflects a remarkable fall in fortune for the maker of one of the most well-known drugs in the world, which is sold as Ozempic for diabetes and ...